Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

BACKGROUND: The biological effect of oral metronomic vinorelbine (mVNB) alone or in combination with endocrine therapy in patients with hormone receptor-positive (HR+)/HER2-negative breast cancer has been scarcely addressed. METHODS: Postmenopausal women with untreated stage I–III HR+/HER2-negative...

Full description

Saved in:
Bibliographic Details
Main Authors: Adamo, Barbara, Bellet, Meritxell, Paré, Laia, Pascual, Tomás, Vidal, Maria, Pérez Fidalgo, José A., Blanch, Salvador, Martinez, Noelia, Murillo, Laura, Gómez-Pardo, Patricia, López-González, Ana, Amillano, Kepa, Canes, Jordi, Galván, Patricia, González-Farré, Blanca, González, Xavier, Villagrasa, Patricia, Ciruelos, Eva, Prat, Aleix
Format: Text
Language:English
Published: BioMed Central 2019
Subjects:
Research Article
Online Access:https://pmc.ncbi.nlm.nih.gov/articles/PMC6751874/
https://pubmed.ncbi.nlm.nih.gov/31533777
http://dx.doi.org/10.1186/s13058-019-1195-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://pmc.ncbi.nlm.nih.gov/articles/PMC6751874/
https://pubmed.ncbi.nlm.nih.gov/31533777
http://dx.doi.org/10.1186/s13058-019-1195-z

Similar Items